GERAGHTY JAMES A 4

What Happened

• James A. Geraghty, a director of Fulcrum Therapeutics, was granted a derivative award of 32,000 shares (reported as an option) on June 30, 2026. The Form 4 records the acquisition as transaction code "A" (award/grant) with a reported price of $0.00 — this is an equity compensation grant (not a market purchase or sale) and does not reflect an immediate cash transaction or sale.

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (appears timely under Form 4 rules).
• Transaction type/code: Award/Grant (A) — 32,000 derivative securities (option).
• Reported price: $0.00 on the Form 4 (the filing footnote confirms this is an option grant).
• Vesting: The option vests in full on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting after the grant, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing.
• No indication of sale, exercise, tax withholding, or 10b5-1 plan in this filing.

Context

• This is a compensation grant to a director — a routine corporate action intended to align management/directors with shareholder interests. It is a derivative award (option) that must vest before becoming exercisable; it is not a purchase signal or immediate liquidity event.